Tyrosine kinase inhibitors and pregnancy

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 6, Issue 1, 2014, Pages

  Abruzzese, Elisabetta ^a   Trawinska, Malgorzata Monika ^a   Perrotti, Alessio Pio ^a   De Fabritiis, Paolo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CONTROL; CANCER MODEL; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; CONCEPTION; CONGENITAL MALFORMATION; DRUG ACTIVITY; DRUG EFFECT; EMBRYOTOXICITY; FERTILITY; FETOTOXICITY; HUMAN; NONHUMAN; PREGNANCY; PREGNANCY OUTCOME; REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW (TOPIC); TERATOGENICITY; UNPLANNED PREGNANCY;

EID: 84920394436     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2014.028     Document Type: Review

References (42)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic Philadelphia chromosome. Science. 1990; 247:824-30 http://dx.doi.org/10.1126/science.2406902
2. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983; 306:239-42 http://dx.doi.org/10.1038/306239a0
3. Deininger MWN, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood. 1997; 90(9):3691-3698
4. Marley SB, Deininger MWN, Davidson RJ, Goldman JM and Gordon MY. The tyrosine kinase inhibitor STI571, like interpheron-a preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Experimental Hematology. 2000; 28:551-557 http://dx.doi.org/10.1016/S0301-472X(00)00142-9
5. Abruzzese E, Breccia M, Latagliata R. Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML). BioDrugs. 2013 Sep 17. [Epub ahead of print]
6. Hehlmann R. Trial of STI571 before proceeding to allografting for CML? Leukemia. 2000; 14:1560-1562, http://dx.doi.org/10.1038/sj.leu.2401874
7. Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP; IRIS investigators. Long-term prognostic significance of earlymolecular response to Imatinib in newly diagnosed chronic myeloid leukemia: ananalysis from the International Randomized Study of Interferon and STI571 (IRIS).Blood. 2010 Nov 11;116(19):3758-65. http://dx.doi.org/10.1182/blood-2010-03-273979
8. Talpaz DM. STI-571 in chronic myelogenous leukaemia. British Journal of Haematology 2002;119:15-24, http://dx.doi.org/10.1046/j.1365-2141.2002.03899.x
9. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec10;27(35):6041-51. http://dx.doi.org/10.1200/JCO.2009.25.0779
10. Nurmio M, Toppari J, Zaman F, Andersson AM, Paranko J, Söder O, Jahnukainen K. Inhibition of tyrosine kinases PDGFR and C-Kit by Imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl 2007;30(4):366-76 http://dx.doi.org/10.1111/j.1365-2605.2007.00755.x
11. He K, Lago MW, Iyer R.A, Shyu WC, Humphreys WG, Christopher LJ. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metabol Disp. 2008;26(12):2564-2570 http://dx.doi.org/10.1124/dmd.108.022764
12. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 2003;40 (2suppl3):21-25 http://dx.doi.org/10.1053/shem.2003.50038
13. Breccia M, Cannella L, Montefusco E, Frustaci A, Pacilli M, Alimena G. Male patients with chronic myeloid leukemia treated with Imatinib involved in healthy pregnancies: report of five cases. Leuk Res 2008;32(3):519-20 http://dx.doi.org/10.1016/j.leukres.2007.07.022
14. Ramasamy K, Hayden J, Lim Z, Mufti GJ, Ho AY. Successful pregnancies involving men with chronic myeloid leukaemia on Imatinib therapy. Br J Haematol 2007;137(4):374-5. http://dx.doi.org/10.1111/j.1365-2141.2007.06542.x
15. Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB; Koller C, Giles F, Keating M, Talpaz M, Cortes J. Pregnancy among patients with CML treated with Imatinib. JCO 2006;24:1204-1208 http://dx.doi.org/10.1200/JCO.2005.04.6557
16. Pye SM, Cortes J, Ault P, Hatfied A, Kantarjian H, Pilot R, Rosti G, Apperly J. The effects of Imatinib on pregnancy outcome. Blood 2008;111:5505-5508 http://dx.doi.org/10.1182/blood-2007-10-114900
17. Laferla JJ. Spontaneous abortion. Clin Obstet Gynaecol. 1986;13:105-114
18. Iqbal J, Ali Z, Khan AU, Aziz Z. Pregnancy outcomes in patients with chronic myeloid leukemia treated with Imatinib mesylate: short report from a developing country. Leuk Lymphoma. 2013 Nov 18. [Epub ahead of print]
19. Zhou L, You JH, Wu W, Li JM, Shen ZX, Wang AH. Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leuk Res. 2013;37(10):1216-21 http://dx.doi.org/10.1016/j.leukres.2013.07.020
20. Conchon M, Sanabani SS, Bendit I, Santos FM, SerpaM, Enrique Dorliac-Llacer P. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. Journal of Hematology & Oncology 2009, 2:42 http://dx.doi.org/10.1186/1756-8722-2-42
21. Etienne G, Milpied B, Réa D, Rigal-Huguet F, Tulliez M, Nicolini FE; French Intergroup of CML (Fi-LMC group). Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group). Bull Cancer. 2010 Aug;97(8):997-1009
22. Cortes J, O'Brien S, Ault P, Borthakur G, Jabbour E, Bradley-Garelik B, Debreczeni K, Yang D, Liu D, Kantarjian H. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood. 2008;112(11). Abstract 3230: Poster presented at: the 50th American Society of Hematology (ASH) Annual Meeting; December 6-9, 2008; San Francisco, USA
23. Kroll T, Ames MB, Pruett JA, Fenske TS. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Leuk Lymphoma 2010;51(9):1751-3. http://dx.doi.org/10.3109/10428194.2010.497982
24. Conchon M, Sanabani SS, Serpa M, Novaes MM, Nardinelli L, Ferreira PB, Dorliac-Lacer PE, Bendit I. Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010;2010:136252 http://dx.doi.org/10.1155/2010/136252
25. Berveiller P, Andreoli A, Mir O, Anselem O, Delezoide AL, Sauvageon H, Chapuis N, Tsatsaris V. A dramatic fetal outcome following transplacental transfer of dasatinib. Anticancer Drugs. 2012; Aug;23(7):754-7 http://dx.doi.org/10.1097/CAD.0b013e328352a8fe
26. Bayraktar S, Morency B, Escalon M.P. Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester. BMJ Case Reports Online Publication; October 21, 2010
27. Choudhary DR, Mishra P, Kumar R, Mahapatra M, Choudry VP. Pregnancy on Imatinib: fatal outcome with meningocele. Annals of Onclology, 2006; 17,1: 178-179 http://dx.doi.org/10.1093/annonc/mdj065
28. Kumar S, Apostolova M, Woolley P.V. A case of chronic myelogenous leukemia in pregnancy characterized by a complex translocation t(9;22;11)(q34;q11.2;q13). Hematol Rep. 2011;3:e27:86-90
29. Shapira T, Pereg D, Lishner M. Blood Rev. How I treat acute and chronic leukemia in pregnancy. 2008 Sep;22(5):247-59.
30. Russel MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ. Imatinib mesylate and metabolite concentration in maternal blood, umbelical cord blood, placenta and breast milk. Journal of Perinatology. 2007; 27, 241-243 http://dx.doi.org/10.1038/sj.jp.7211665
31. Ali R, Ozkalemkas F, Kimya Y, Koksal N, Ozkocaman V, Gulten T, Yorulmaz H, Tunali A. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet. 2009 Aug;280(2):169-75. 2008.
32. Kronenberger R, Schleyer E, Bornhauser M, Ehniger G, Gatterman N, Blum S. Imatinib in brest milk. Annals of Hematology. 2009; 88:1265-1266 http://dx.doi.org/10.1007/s00277-009-0754-2
33. Pitkin RM, White DL. Platelet and leukocyte counts in pregnancy. JAMA. 1979;243(24):2696-2698 http://dx.doi.org/10.1001/jama.1979.03300240036023
34. Pons JC, Lebon P, Frydman R, Delfraissy JF. Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage. Fetal Diagn Ther 1995; 10: 7-10. http://dx.doi.org/10.1159/000264183
35. Patel M, Dukes IA, Hull JC. Use of hydroxyurea in chronic myeloid leukemia during pregnancy: A case report. Am J Obstet Gynecol 1991;165: 565-566. http://dx.doi.org/10.1016/0002-9378(91)90285-Y
36. Webb MJ, Jafta D. Imatinib use in pregnancy. Turk J Haematol. 2012 Dec;29(4):405-8. http://dx.doi.org/10.5505/tjh.2012.82542
37. Uruakpa, F; Ismond, MAH; Akobundu, ENT. Colostrum and its benefits: a review". Nutrition Research. 2002; 22 (6): 755. http://dx.doi.org/10.1016/S0271-5317(02)00373-1
38. Garderet L, Santacruz R, Barbu V, van den Akker J, Carbonne B, Gorin NC. Two successful pregnancies in a chronic myeloid leukemia patient treated with Imatinib. Hematologica. 2007; 2003 (88):9-10 http://dx.doi.org/10.3324/haematol.10935
39. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, Gardembas M, Mahon FX. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia in complete molecular remission for more than 2 years. Blood. 2007; 109(1):58-60 http://dx.doi.org/10.1182/blood-2006-03-011239
40. Sorà F, De Matteis S, Bajer J, D'alò F, Leone G, Sica S. Persistence of molecular remission throughout pregnancy in CML after Imatinib. Leuk Res. 2009 Jun;33(6):e6-7 http://dx.doi.org/10.1016/j.leukres.2008.09.012
41. Apperly J. Issues of Imatinib and pregnancy outcome. Journal of the National Comprehensive cancer Network. 2009, 7(10): 1-9
42. Apperly J. CML in pregnancy and childhood. Best practice & Research Clinical Hematology. 2009,; 455-475